Capivasertib for Solid Tumors

"This clinical trial is seeking patients in the 18 to 130 age group. Patients below the age of consent may be eligible for 343 trials, and those above 65 years old can apply for 2449 different trials."

"At present, 85 clinical trials are underway in order to research Capivasertib. Of these experiments, 14 have advanced to Phase 3 status. While most of the studies for this treatment take place in Porto Alegre and California, a total of 4908 sites worldwide are conducting tests on its efficacy."

"This clinical trial seeks 21 individuals aged 18 to 130 with solid tumors. To be eligible, participants must satisfy the following conditions: have locally advanced inoperable or metastatic tumors that can feasibly receive capivasertib treatment; possess an Eastern Cooperative Oncology Group/World Health Organization performance status between 0 and 1; hold a minimum life expectancy of 12 weeks; maintain a body mass index ranging from 18 to 32 kg/m^2; and have at least one lesion discernible through computed tomography/magnetic resonance imaging or plain X-ray scans."

"The enrollment window for this clinical trial has been closed. It was first posted on October 15, 2021 and most recently amended on October 17, 2022. If you are searching for alternate trials, 2585 studies involving tumors of a solid nature have openings and 85 trials utilizing Capivasertib require participants."

"The safety of Capivasertib is rated low; a score of 1 was given, as this trial is currently in Phase One and there remains insufficient evidence to support its efficacy."

"This trial has concluded recruitment and the posting on clinicaltrials.gov was last updated October 17th 2022. If you are seeking other medical studies, there are currently 2585 trials recruiting patients with tumors and 85 for Capivasertib actively enlisting participants."

"Capivasertib is primarily used to treat anxiolysis, but has also been prescribed for the induction of amnesia and convulsive status epilepticus."

"Information provided by the clinical trial's sponsor, AstraZeneca, indicates that their primary outcome measure is Midazolam Cmax. This will be monitored across a 29-day period known as Cycle 1. Secondary outcomes include Midazolam tmax (time to peak or max concentration), Midazolam AUClast (area under curve from 0 to last quantifiable concentration) and Capivasertib AUCτ (area under curve in dose interval)."

"This trial is currently being conducted at 6 different sites, such as Dallas, Austin and Durham. Potential participants should select the centre closest to them in order to reduce any travel related expenses associated with participation."